The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Identifying The Mechanisms By Which Ascorbate Stimulates Cellular Iron Uptake From Transferrin.
Funder
National Health and Medical Research Council
Funding Amount
$302,123.00
Summary
Vitamin C (ascorbate)-deficiency leads to anaemia and other symptoms of scurvy. Iron supplementation cannot alone correct this anaemia, with ascorbate being crucial. Almost all iron in plasma is bound to transferrin, and I have recent data showing that ascorbate stimulates transferrin-iron uptake. This research will identify how this stimulation occurs. This work has important biomedical implications for understanding iron uptake and anaemia, which affects 500 million people globally.
Preclinical Assessment Of The Potential Utility Of Oxytocin And A Novel Oxytocin Agonist For The Treatment Of Substance Use Disorders And Social Dysfunction
Funder
National Health and Medical Research Council
Funding Amount
$320,891.00
Summary
Recent work has highlighted the utility of stimulating the brain oxytocin (OT) system in the treatment of numerous psychiatric disorders, in particular substance use disorders and social disorders (e.g. autism). I will focus on the continuation of two interrelated projects during my Fellowship: (1) preclinical exploration of OT as a novel treatment for alcohol use disorders; and (2) further developing our novel non-peptide OT agonist (SOC-1), which has profound pro-social effects.